Japan Vaccine 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
72 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
NCT03493776: Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation

Active, not recruiting
4
50
Canada
VZV subunit vaccine
Deepali Kumar
Varicella Zoster Vaccine
09/19
04/21
2019-002529-31: Safety and efficiacy of a new chickenpox and shingles vaccine in patients who have undergone kidney transplantation

Not yet recruiting
4
50
Europe
Shingrix, Suspension for injection, Shingrix
Oslo University Hospital, Oslo University Hospital, Landsforeningen for nyresyke og transplanterte
Kidney transplant recipients who are varicella-zoster sero-negative. The study aim to evaluate if the Shingrix vaccine will produce immune response in varicella naive kidney transplant recipients, Patients who have received a kidney transplant and have not experienced chickenpox. The study will investigate if the Shingrix vaccine is able to protect the patient against chickenpoxation, Body processes [G] - Immune system processes [G12]
 
 
NCT05007041: Simultaneous RZV and aIIV4 Vaccination

Completed
4
267
US
FLUAD® Quadrivalent, Influenza Vaccine, Adjuvanted (Quadrivalent), aIIV4, Fluzone® High-Dose Quadrivalent, High-Dose Quadrivalent Influenza Vaccine, HD-IIV4, SHINGRIX®, Zoster Vaccine Recombinant, Adjuvanted (RZV)
Duke University, Centers for Disease Control and Prevention, Johns Hopkins University
Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
03/23
06/23
NCT04169009: Persistence of Protection by Shingrix

Completed
4
105
US
Zostavax, Shingrix
University of Colorado, Denver, National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster
03/23
06/24
2020-005682-13: Age differences in flu and shingles vaccine response Leeftijdsgebonden verschillen tussen de afweerreactie na griep- en gordelroosvaccinatie

Not yet recruiting
4
140
Europe
Concentrate and solvent for solution for injection, Solution for injection, Shingrix, GSK, Fluarix Tetra, GSK
Radboudumc, GlaxoSmithKline
Influenza Herpes Zoster, The interventions has the objective to better understand the immune response of the interventions, Diseases [C] - Virus Diseases [C02]
 
 
NCT04869982: Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years

Completed
4
6138
RoW
RZV, Placebo
GlaxoSmithKline
Herpes Zoster
04/23
04/23
NCT03798691: Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab

Completed
4
33
US
Shingrix, Recombinant zoster vaccine
University of Wisconsin, Madison, Boston Medical Center
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Herpes Zoster
10/23
09/24

Completed
4
110
Europe
COVID-19 vaccination, the monovalent Omicron XBB.1.5 COVID-19 mRNA vaccination
University Medical Center Groningen, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Radboud University Medical Center, Erasmus Medical Center, UMC Utrecht, Leiden University Medical Center, Maastricht University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Dutch Kidney Foundation
COVID-19 Vaccines, Varicella Zoster Vaccine, Vaccine Response, Immunosuppression
12/23
02/24
NCT04403139: VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination

Active, not recruiting
4
50
US
Shingrix
University of Washington, National Institute on Aging (NIA)
Varicella Zoster Virus Infection
02/26
02/26
NCT06162494: Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients

Enrolling by invitation
4
120
US
Recombinant Zoster Vaccine, Shingrix
Ann & Robert H Lurie Children's Hospital of Chicago, Children's Hospital Colorado, Children's Hospital Medical Center, Cincinnati
Varicella Zoster
03/27
09/27
NCT03591770: Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib

Terminated
4
15
US
SHINGRIX, Recombinant zoster vaccine
Boston Medical Center
Inflammatory Bowel Diseases
07/24
07/24
NCT05170399: Vaccine Responses in Patients With B Cell Malignancies

Recruiting
4
500
US
Fluzone, Shingrix, Flucelvax, Afluria, PREVNAR 13, Heplisav -B, Pfizer-COVID-19 Vaccine, FluLaval, Fluarix, PNEUMOVAX 23, PREVNAR 20, AREXVY, ABRYSVO
National Heart, Lung, and Blood Institute (NHLBI)
Lymphoma
08/25
08/25
NCT04748939: Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT

Not yet recruiting
4
140
RoW
recombinant subunit herpes zoster vaccine, Shingrix
Tuen Mun Hospital
Herpes Zoster
12/25
07/26
Shingr'HIV, NCT05575830: Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched Controls

Active, not recruiting
4
225
Europe
Recombinant Zoster Vaccine, (Shingrix® )
Calmy Alexandra
RZV Vaccine (Shingrix ®)
05/25
03/26
NCT06224270: Study of Response to Zoster Vaccine in Adults with Inflammatory Bowel Disease Treated with Medications

Withdrawn
4
264
US
Adjuvanted Recombinant Zoster Vaccine (RZV)
University of Wisconsin, Madison, GlaxoSmithKline
Inflammatory Bowel Diseases, IBD
09/27
09/27
MSHINGVAX, NCT05596526: Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients

Recruiting
4
100
Europe
recombinant zoster vaccine, Shingrix®
Prof Patrice Lalive
Shingles, Zoster
12/24
12/25
HZ-REUMA, NCT06763783: Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases

Enrolling by invitation
4
240
Europe
Shingrix, vaccination with 2 doses of Shingrix vaccine
Region Skane, GlaxoSmithKline
Systemic Vasculitis, Spondylarthropathies, Psoriatic Arthritis, Scleroderma, Polymyalgia Rheumatica (PMR), Juvenile Chronic Arthritis, Polyarthritis, SLE, Giant Cell Arteritis (GCA)
12/29
06/34
RZVRheum, NCT05879419: Recombinant Herpes Zoster Vaccine in Patients with Autoimmune Rheumatic Diseases

Active, not recruiting
4
2005
RoW
Recombinant Herpes Zoster Vaccine (RZV), Shingrix®, MTX Discontinuation, MMF Discontinuation, Placebo, MTX maintain, MMF maintain
University of Sao Paulo General Hospital, GlaxoSmithKline
Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis, Systemic Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Vasculitis, Systemic, Juvenile Idiopathic Arthritis, Dermatomyositis, Juvenile, Behçet Disease
05/25
05/27
NCT05550194: VZV in the Enteric Nervous System: Pathogenesis and Consequences

Recruiting
4
40
US
ValACYclovir 1000 MG, Valtrex, Shingrix, Zoster vaccine recombinant
Vanderbilt University Medical Center, Columbia University
Achalasia
08/26
08/26
NCT05559671: Safety of the Herpes Zoster Subunit Vaccine in Lupus

Recruiting
4
224
US
Herpes Zoster Subunit (HZ/su) Vaccine, SHINGRIX, Placebo
NYU Langone Health
Systemic Lupus Erythematosus
01/27
01/27
NCT04176939 / 2019-001815-21: A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response

Active, not recruiting
3
68
Europe, Canada, RoW
HZ/su vaccine (GSK1437173A)
GlaxoSmithKline
Herpes Zoster
08/22
08/24
NCT05219253: A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India

Completed
3
288
RoW
HZ/su, Placebo
GlaxoSmithKline
Herpes Zoster
10/22
12/22
NCT02723773 / 2015-001778-17: A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

Completed
3
7534
Europe, Canada, Japan, US, RoW
Herpes Zoster Vaccine GSK1437173A
GlaxoSmithKline
Herpes Zoster
06/23
06/23
NCT04128189: Shingrix in Renal Transplant Recipients

Recruiting
3
132
US
Shingrix
University of Colorado, Denver
Kidney Transplant Recipient Response to Shingrix Vaccine
01/26
09/26
NCT05371080 / 2021-005319-30: A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

Active, not recruiting
3
3038
Europe, Canada, Japan, US, RoW
HZ/su vaccine
GlaxoSmithKline
Herpes Zoster
08/27
08/27
NCT04091451 / 2016-000744-34: Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster

Completed
3
1430
Europe, RoW
Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A), Placebo
GlaxoSmithKline
Herpes Zoster
02/24
02/24
RSV OA=ADJ-020, NCT05966090: A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults

Completed
3
530
Canada, US
RSVPreF3 OA investigational vaccine, Respiratory Syncytial Virus PreFusion protein 3 Older Adults vaccine, HZ/su vaccine, Herpes Zoster recombinant subunit vaccine, Shingrix
GlaxoSmithKline
Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
02/24
07/24
PISSARRO, NCT06890416: A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults

Active, not recruiting
3
526
US
RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, ABRYSVO, RSVpreF, PF-06928316, HZ/su VACCINE, SHINGRIX, RZV, HZ/su
Pfizer
Respiratory Syncytial Virus (RSV)
09/25
09/25
NCT06001606: Immunogenicity, Reactogenicity of Shingrix in SLE

Recruiting
3
63
RoW
Shingrix, Placebo
Seoul National University Hospital
Zoster, Systemic Lupus Erythematosus, Vaccine Reaction
04/25
04/25
NCT03702231: Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Completed
2
116
US
Zoster Vaccine Recombinant, Adjuvanted, SHINGRIX
National Heart, Lung, and Blood Institute (NHLBI)
Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
09/20
07/23
NCT05082688: Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)

Completed
2
148
Europe
Herpes zoster vaccination (Shingrix, GSK), Influenza Vaccine (Fluarix Tetra Northern Hemisphere 2021 or 2022, GSK), Placebo
Radboud University Medical Center, GlaxoSmithKline
Influenza, Herpes Zoster
05/23
05/23
2022-003477-36: Safety and immunologic response of SHIngrix VAccination in patients suffering from Psoriasis or Psoriatic arthritis (SHIVAP) Sicherheit und Immunantwort der Shingrix-Impfung bei Patienten mit Schuppenflechte oder Schuppenflechte mit Gelenkentzündung

Not yet recruiting
2
336
Europe
Powder and suspension for suspension for injection, Shingrix
Justus-Liebig University Giessen - KKS Marburg-Giessen, GSK
Psoriasis vulgaris and/or psoriatric arthritis, Psoriasis and/or psoriatric arthritis Schuppenflechte und/oder Schuppenflechte mit Gelenkentzündung, Body processes [G] - Immune system processes [G12]
 
 
BMS-188667, NCT03604406: The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept

Active, not recruiting
2
154
US
Varicella Zoster Vaccine, Zostavax, Placebo Injection, Shingrix
Kevin Winthrop, University of Alabama at Birmingham, Bristol-Myers Squibb
Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis
06/25
09/26
NCT04047979: Systems Biology of Zoster Vaccine

Completed
2
38
US
Shingrix®
Emory University, National Institute of Allergy and Infectious Diseases (NIAID)
Zoster, Zoster Varicella, Shingles, Chicken Pox
04/23
10/23
NCT05856084: Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above

Active, not recruiting
2
924
RoW
Low dose Recombinant Herpes Zoster Vaccine (CHO cells), High dose Recombinant Herpes Zoster Vaccine (CHO cells), Positive control, Shingrix®, Placebo, Normal Saline for injection
MAXVAX Biotechnology Limited Liability Company, Henan Center for Disease Control and Prevention
Herpes Zoster
02/24
03/26
NCT05304351: Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

Recruiting
2
1516
US
Amezosvatein Antigen High Dose Arm A, Amezosvatein Antigen Low Dose Arm B, Shingrix, Amezosvatein Adjuvant Dose Arm D, Amezosvatein Adjuvant Dose Arm F, Amezosvatein Adjuvant Dose Arm H, Amezosvatein Adjuvant Dose Arm J, Amezosvatein Adjuvant Dose Arm L
Curevo Inc, Mogam Biotechnology Research Institute, Green Cross Corporation
Herpes Zoster, Shingles
06/26
03/32
JCXH-105-021, NCT06581575: A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

Active, not recruiting
2
467
US
JCXH-105, Shingrix
Immorna Biotherapeutics, Inc., Tigermed Consulting Co., Ltd
Herpes Zoster (HZ), Infectious Diseases, Shingles
08/25
08/25
NCT05554068: Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Recruiting
2
100
US
Shingrix
Loyola University
Shingles
03/25
11/26
Allo, NCT05775718: Shingrix In Recipients of geneic Transplants

Recruiting
2
55
US
Zoster Vaccine Recombinant, Shingrix
University of Colorado, Denver, GlaxoSmithKline
Bone Marrow Transplant, Stem Cell Transplant
12/25
12/30
NCT05703607: A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

Active, not recruiting
2
900
US
Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection, Candidate 3: PF-07921186: VZV modRNA Suspension for Injection, Shingrix, Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection
Pfizer, BioNTech SE
Shingles, Herpes Zoster Infection, Human
02/26
08/30
NCT06569823: Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults

Recruiting
1/2
440
RoW
Z-1018, Shingrix
Dynavax Technologies Corporation
Shingles, Herpes Zoster, Vaccine-Preventable Diseases
09/26
09/26
NCT05701800: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

Active, not recruiting
1/2
659
US
mRNA-1468, Placebo, Saline, Shingrix
ModernaTX, Inc.
Herpes Zoster
06/26
06/26
NCT06801509: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine

Not yet recruiting
1/2
540
RoW
Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose, Recombinant Herpes Zoster Vaccine (SCTV04C) High-Dose, Placebo control: Saline, Shingrix®, Ganwei®
Sinocelltech Ltd.
Herpes Zoster
11/25
10/27
NCT06932523: A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals

Not yet recruiting
1/2
645
NA
Recombinant herpes zoster vaccine with low-dose adjuvant, Recombinant herpes zoster vaccine with high-dose adjuvant, Low-dose adjuvant, High-dose adjuvant, Shingrix (GSK), Normal Saline
Shanghai Institute Of Biological Products
Herpes Zoster (HZ)
06/26
12/27
NCT05580458: Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population

Recruiting
1/2
225
US
Shingrix
National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster
02/27
10/27
NH-Shingrix, NCT04523246: Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents

Completed
1
217
US
SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted), Zoster Vaccine Recombinant, Adjuvanted, Normal Saline, saline
University of Oklahoma, Oklahoma Medical Research Foundation
Herpes Zoster, Allergy and Immunology, Corona Virus Infection
12/21
05/23
NCT06137755: Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above

Recruiting
1
32
RoW
CVI-VZV-001, Shingrix
CHA Vaccine Institute Co., Ltd.
Vaccine-Preventable Diseases, Herpes Zoster
03/25
03/25
NCT05769049: The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell)

Completed
1
48
RoW
REC610, Recombinant Zoster Vaccine (CHO cell), Shingrix
Jiangsu Rec-Biotechnology Co., Ltd.
Herpes Zoster
12/23
12/23
NCT05718037: Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine

Not yet recruiting
1
40
NA
Recombinant Zoster Vaccine, BV211, Placebo, Zoster Vaccine Recombinant, Adjuvanted, Shingrix
Wuhan BravoVax Co., Ltd., Shanghai BravoBio Co., Ltd.
Herpes Zoster
01/24
07/24
JCXH-105, NCT05871541: A First-in-Human Study to Evaluate , an SrRNA-based Herpes Zoster Vaccine

Completed
1
75
US
JCXH-105, Active Control (Shingrix)
Immorna Biotherapeutics, Inc., ICON plc
Herpes Zoster (HZ), Shingles, Infectious Disease
03/24
03/24
LYB004-CT-AUS-101, NCT06335849: A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 50 to 70 Years

Active, not recruiting
1
48
RoW
LYB004 25µg, LYB004 50µg, SHINGRIX
Guangzhou Patronus Biotech Co., Ltd., Yantai Patronus Biotech Co., Ltd.
Herpes Zoster
09/25
09/25
NCT06375512: A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

Active, not recruiting
1
150
US, RoW
HZ Vaccine (IN001), Placebo, Shingrix
Shenzhen Shenxin Biotechnology Co., Ltd
Herpes Zoster
12/25
06/26
NCT06409494: Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years

Active, not recruiting
1
72
RoW
EuHZV, Shingrix
EuBiologics Co.,Ltd
Varicella Zoster Virus Infection, Herpes Zoster
07/25
05/26
NCT05991427: A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years

Completed
1
65
Canada
Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV), Zoster Vaccine Recombinant, Adjuvanted (Shingrix), ChAdOx1-VZV, Shingrix, IH ChAdOx1-VZV, IH saline
CanSino Biologics Inc.
Herpes Zoster
11/24
11/24
MKKCT-100-001, NCT05636436: Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above

Active, not recruiting
1
132
RoW
Low Dose Recombinant Herpes Zoster Vaccine (CHO cells), High Dose Recombinant Herpes Zoster Vaccine (CHO cells), Low dose adjuvant, High dose adjuvant, Positive control, Shingrix®, Placebo, Saline for injection
MAXVAX Biotechnology Limited Liability Company, Henan Center for Disease Control and Prevention
Herpes Zoster
12/24
12/24
NCT06874842: Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older

Recruiting
1
92
RoW
Low dose antigen and low dose adjuvant of LYB004, Low dose antigen and high dose adjuvant of LYB004, High dose antigen and low dose adjuvant of LYB004, High dose antigen and high dose adjuvant of LYB004, Placebo, Positive control, Shingrix®
Guangzhou Patronus Biotech Co., Ltd.
Herpes Zoster (HZ)
02/26
10/26
SIR ZOSTER, NCT06262776: Safety and Immunogenicity of Recombinant Zoster Vaccine for Kidney Transplant Recipients

Recruiting
N/A
120
RoW
Recombinant zoster vaccine adjuvanted (SHINGRIX)
Central Adelaide Local Health Network Incorporated, National Health and Medical Research Council, Australia, University of Adelaide, Royal Prince Alfred Hospital, Sydney, Australia
Immunosuppression, Vaccine Response Impaired
12/25
12/26
NCT06238726: Nudging Patients to Increase Shingles Vaccination

Completed
N/A
50786
US
Reminder
Geisinger Clinic, Massachusetts Institute of Technology, National Bureau of Economic Research, Inc.
Shingles, Vaccination Behavior, Behavior, Health
06/25
06/25
CLL2624, NCT06364033: Biological and Clinical Efficacy of Shingrix in Patients With CLL

Not yet recruiting
N/A
312
Europe
serologic response evaluation
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL-like MBL, Varicella-zoster Virus Reactivation
11/25
10/28
NCT06574594: Effect of MTX Discontinuation on Shingrix Response in RA

Recruiting
N/A
110
RoW
Methotrexate
Konkuk University Medical Center
Rheumatoid Arthritis
12/25
12/25
NCT06596148: Improving Shingrix Vaccination Among US Veterans Receiving Immunosuppression

Enrolling by invitation
N/A
130
US
Access to Shingrix dashboard
University of California, San Francisco, San Francisco Veterans Affairs Medical Center
Immunosuppresion
03/26
06/26
NCT05811754: Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions

Not yet recruiting
N/A
2844
NA
Data collection
GlaxoSmithKline, Harvard Pilgrim Health Care Institute
Herpes Zoster
05/28
04/29
Cervarix (recombinant human papillomavirus bivalent vaccine) / GSK, Japan Vaccine
2007-006651-39: A phase IV, randomized, open-label, controlled, post-licensure study to evaluate the safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix®) when administered intramuscularly according to a 0, 1, 6-month schedule in females aged 18-25 years.

Ongoing
4
100000
Europe
Cervarix ™, HPV-16/18 L1 VLP AS04 vaccine, Cervarix ™, Havrix®, Cervarix ™, Havrix®
GlaxoSmithKline Biologicals
No medical condition will be investigated in this study. The study will follow vaccinated females and collect safety data focussing on autoimmune diseases, pregnancy outcomes and SAEs considered to be related to the vaccine.
 
 
2008-006773-32: A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving Cervarix(TM) or Gardasil(TM) Human Papillomavirus vaccines

Ongoing
4
400
Europe
Cervarix, Gardasil, Cervarix, Gardasil, Cervarix, Gardasil
Health Protection Agency
This study will investigate vaccines that prevent premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18. This study will investigate whether immunisation against infection with HPV 16 and 18 may impact on other oncogenic HPV types, through cross-protection.
 
 
NCT03675256: The KEN SHE Study on HPV-vaccine Efficacy

Active, not recruiting
4
2275
RoW
immediate Gardasil 9, delayed MenVeo vaccine, immediate MenVeo vaccine, delayed Gardasil 9, immediate Cervarix, delayed MenVeo vaccine
Massachusetts General Hospital, Bill and Melinda Gates Foundation, Kenya Medical Research Institute
Papillomavirus Infections
02/24
02/24
NCT03180034: Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study

Active, not recruiting
4
28000
RoW
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Adacel, Daptacel, Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine Adsorbed, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine, DTaP, Infanrix, Tripedia, Questionnaire Administration, Recombinant Human Papillomavirus Bivalent Vaccine, Cervarix, GSK-580299, HPV 16/18 L1 VLP/AS04 VAC, HPV-16/18 VLP/AS04 Vaccine, Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine, Human Papillomavirus Bivalent Types 16 and 18 Vaccine, Recombinant, Human Papillomavirus Vaccine L1 16,18, Human Papillomavirus Vaccine, L1 Type 16, 18, Recombinant HPV Bivalent Vaccine, Recombinant Human Papillomavirus Nonavalent Vaccine, Gardasil 9, Nonavalent HPV VLP Vaccine, Recombinant HPV Nonavalent Vaccine, Recombinant Human Papillomavirus 9-valent Vaccine
National Cancer Institute (NCI), Bill and Melinda Gates Foundation
Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma
08/25
08/25
PRISMA, NCT05237947: Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The ESCUDDO Trial

Active, not recruiting
4
5000
RoW
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Adacel, Daptacel, Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine Adsorbed, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine, DTaP, Infanrix, Tripedia, Questionnaire Administration, Recombinant Human Papillomavirus Bivalent Vaccine, Cervarix, GSK-580299, HPV 16/18 L1 VLP/AS04 VAC, HPV-16/18 VLP/AS04 Vaccine, Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine, Human Papillomavirus Bivalent Types 16 and 18 Vaccine, Recombinant, Human Papillomavirus Vaccine L1 16,18, Human Papillomavirus Vaccine, L1 Type 16, 18, Recombinant HPV Bivalent Vaccine, Recombinant Human Papillomavirus Nonavalent Vaccine, Gardasil 9, Nonavalent HPV VLP Vaccine, Recombinant HPV Nonavalent Vaccine, Recombinant Human Papillomavirus 9-valent Vaccine
National Cancer Institute (NCI)
Human Papillomavirus-Related Cervical Carcinoma
05/26
05/26
NCT02834637: A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls

Active, not recruiting
3
930
RoW
bivalent HPV vaccine, Cervarix, nonavalent HPV vaccine, Gardasil9
London School of Hygiene and Tropical Medicine, University of York, Institut Català d'Oncologia, National Cancer Institute (NCI), Karolinska Institutet, Technische Universität Berlin, Tanzanian National Institute for Medical Research, University of Glasgow
Human Papilloma Virus
01/20
03/27
PRIMAVERA-ESCUDDO, NCT03728881: Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the Trial

Completed
3
1240
RoW
Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine, Gardasil, Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle vaccine, quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine, Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine, V501, Recombinant Human Papillomavirus Bivalent Vaccine, Cervarix, GSK-580299, HPV 16/18 L1 VLP/AS04 VAC, HPV-16/18 VLP/AS04 Vaccine, Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine, Human Papillomavirus Bivalent Types 16 and 18 Vaccine, Recombinant, Human Papillomavirus Vaccine L1 16,18, Human Papillomavirus Vaccine, L1 Type 16, 18, Recombinant HPV Bivalent Vaccine
National Cancer Institute (NCI)
Human Papillomavirus-Related Cervical Carcinoma
09/22
04/24
2007-000164-24: Safety and immunogenicity study of GlaxoSmithKline Biologicals’ HPV-16/18/33/58 L1 VLP vaccine in healthy female subjects aged 18–25 years

Not yet recruiting
1/2
540
Europe
HPV-16/18/33/58 L1 VLP AS04 vaccine, HPV-16/18/33/58 L1 VLP AS01E vaccine, HPV-16/18/33/58 L1 VLP AS02W vaccine, HPV-16/18/33/58 L1 VLP AS04 vaccine, HPV-16/18/33/58 L1 VLP AS01E vaccine, HPV-16/18/33/58 L1 VLP AS02W vaccine, Suspension for injection, Cervarix
GlaxoSmithKline Biologicals, GlaxoSmithKline Biologicals
Healthy volunteers, Cervical cancer, Diseases [C] - Cancer [C04]
 
 
HVRRICANE, NCT04301154: Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth

Active, not recruiting
1
25
RoW
HIVIS DNA/MVA-CMDR, HIVIS DNA + Cervarix and MVA-CMDR, Cervarix
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bambino Gesù Hospital and Research Institute, PENTA Foundation, Johns Hopkins University, University of Miami, Leidos Biomedical Research, Inc., Case Western Reserve University, Karolinska Institutet, Walter Reed Army Institute of Research (WRAIR), Armed Forces Research Institute of Medical Sciences, Thailand, University of Padova, Chulalongkorn University
HIV Infections
10/23
02/25
IVIHPV1, NCT03747770: Effectiveness of Single Dose or Two Doses of Bivalent HPV Vaccine in Thailand

Enrolling by invitation
N/A
18000
RoW
Bivalent HPV vaccine CERVARIX®
International Vaccine Institute, Ministry of Health, Thailand
Healthy
12/22
06/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
NCT03493776: Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation

Active, not recruiting
4
50
Canada
VZV subunit vaccine
Deepali Kumar
Varicella Zoster Vaccine
09/19
04/21
2019-002529-31: Safety and efficiacy of a new chickenpox and shingles vaccine in patients who have undergone kidney transplantation

Not yet recruiting
4
50
Europe
Shingrix, Suspension for injection, Shingrix
Oslo University Hospital, Oslo University Hospital, Landsforeningen for nyresyke og transplanterte
Kidney transplant recipients who are varicella-zoster sero-negative. The study aim to evaluate if the Shingrix vaccine will produce immune response in varicella naive kidney transplant recipients, Patients who have received a kidney transplant and have not experienced chickenpox. The study will investigate if the Shingrix vaccine is able to protect the patient against chickenpoxation, Body processes [G] - Immune system processes [G12]
 
 
NCT05007041: Simultaneous RZV and aIIV4 Vaccination

Completed
4
267
US
FLUAD® Quadrivalent, Influenza Vaccine, Adjuvanted (Quadrivalent), aIIV4, Fluzone® High-Dose Quadrivalent, High-Dose Quadrivalent Influenza Vaccine, HD-IIV4, SHINGRIX®, Zoster Vaccine Recombinant, Adjuvanted (RZV)
Duke University, Centers for Disease Control and Prevention, Johns Hopkins University
Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
03/23
06/23
NCT04169009: Persistence of Protection by Shingrix

Completed
4
105
US
Zostavax, Shingrix
University of Colorado, Denver, National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster
03/23
06/24
2020-005682-13: Age differences in flu and shingles vaccine response Leeftijdsgebonden verschillen tussen de afweerreactie na griep- en gordelroosvaccinatie

Not yet recruiting
4
140
Europe
Concentrate and solvent for solution for injection, Solution for injection, Shingrix, GSK, Fluarix Tetra, GSK
Radboudumc, GlaxoSmithKline
Influenza Herpes Zoster, The interventions has the objective to better understand the immune response of the interventions, Diseases [C] - Virus Diseases [C02]
 
 
NCT04869982: Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years

Completed
4
6138
RoW
RZV, Placebo
GlaxoSmithKline
Herpes Zoster
04/23
04/23
NCT03798691: Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab

Completed
4
33
US
Shingrix, Recombinant zoster vaccine
University of Wisconsin, Madison, Boston Medical Center
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Herpes Zoster
10/23
09/24

Completed
4
110
Europe
COVID-19 vaccination, the monovalent Omicron XBB.1.5 COVID-19 mRNA vaccination
University Medical Center Groningen, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Radboud University Medical Center, Erasmus Medical Center, UMC Utrecht, Leiden University Medical Center, Maastricht University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Dutch Kidney Foundation
COVID-19 Vaccines, Varicella Zoster Vaccine, Vaccine Response, Immunosuppression
12/23
02/24
NCT04403139: VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination

Active, not recruiting
4
50
US
Shingrix
University of Washington, National Institute on Aging (NIA)
Varicella Zoster Virus Infection
02/26
02/26
NCT06162494: Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients

Enrolling by invitation
4
120
US
Recombinant Zoster Vaccine, Shingrix
Ann & Robert H Lurie Children's Hospital of Chicago, Children's Hospital Colorado, Children's Hospital Medical Center, Cincinnati
Varicella Zoster
03/27
09/27
NCT03591770: Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib

Terminated
4
15
US
SHINGRIX, Recombinant zoster vaccine
Boston Medical Center
Inflammatory Bowel Diseases
07/24
07/24
NCT05170399: Vaccine Responses in Patients With B Cell Malignancies

Recruiting
4
500
US
Fluzone, Shingrix, Flucelvax, Afluria, PREVNAR 13, Heplisav -B, Pfizer-COVID-19 Vaccine, FluLaval, Fluarix, PNEUMOVAX 23, PREVNAR 20, AREXVY, ABRYSVO
National Heart, Lung, and Blood Institute (NHLBI)
Lymphoma
08/25
08/25
NCT04748939: Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT

Not yet recruiting
4
140
RoW
recombinant subunit herpes zoster vaccine, Shingrix
Tuen Mun Hospital
Herpes Zoster
12/25
07/26
Shingr'HIV, NCT05575830: Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched Controls

Active, not recruiting
4
225
Europe
Recombinant Zoster Vaccine, (Shingrix® )
Calmy Alexandra
RZV Vaccine (Shingrix ®)
05/25
03/26
NCT06224270: Study of Response to Zoster Vaccine in Adults with Inflammatory Bowel Disease Treated with Medications

Withdrawn
4
264
US
Adjuvanted Recombinant Zoster Vaccine (RZV)
University of Wisconsin, Madison, GlaxoSmithKline
Inflammatory Bowel Diseases, IBD
09/27
09/27
MSHINGVAX, NCT05596526: Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients

Recruiting
4
100
Europe
recombinant zoster vaccine, Shingrix®
Prof Patrice Lalive
Shingles, Zoster
12/24
12/25
HZ-REUMA, NCT06763783: Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases

Enrolling by invitation
4
240
Europe
Shingrix, vaccination with 2 doses of Shingrix vaccine
Region Skane, GlaxoSmithKline
Systemic Vasculitis, Spondylarthropathies, Psoriatic Arthritis, Scleroderma, Polymyalgia Rheumatica (PMR), Juvenile Chronic Arthritis, Polyarthritis, SLE, Giant Cell Arteritis (GCA)
12/29
06/34
RZVRheum, NCT05879419: Recombinant Herpes Zoster Vaccine in Patients with Autoimmune Rheumatic Diseases

Active, not recruiting
4
2005
RoW
Recombinant Herpes Zoster Vaccine (RZV), Shingrix®, MTX Discontinuation, MMF Discontinuation, Placebo, MTX maintain, MMF maintain
University of Sao Paulo General Hospital, GlaxoSmithKline
Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis, Systemic Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Vasculitis, Systemic, Juvenile Idiopathic Arthritis, Dermatomyositis, Juvenile, Behçet Disease
05/25
05/27
NCT05550194: VZV in the Enteric Nervous System: Pathogenesis and Consequences

Recruiting
4
40
US
ValACYclovir 1000 MG, Valtrex, Shingrix, Zoster vaccine recombinant
Vanderbilt University Medical Center, Columbia University
Achalasia
08/26
08/26
NCT05559671: Safety of the Herpes Zoster Subunit Vaccine in Lupus

Recruiting
4
224
US
Herpes Zoster Subunit (HZ/su) Vaccine, SHINGRIX, Placebo
NYU Langone Health
Systemic Lupus Erythematosus
01/27
01/27
NCT04176939 / 2019-001815-21: A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response

Active, not recruiting
3
68
Europe, Canada, RoW
HZ/su vaccine (GSK1437173A)
GlaxoSmithKline
Herpes Zoster
08/22
08/24
NCT05219253: A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India

Completed
3
288
RoW
HZ/su, Placebo
GlaxoSmithKline
Herpes Zoster
10/22
12/22
NCT02723773 / 2015-001778-17: A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

Completed
3
7534
Europe, Canada, Japan, US, RoW
Herpes Zoster Vaccine GSK1437173A
GlaxoSmithKline
Herpes Zoster
06/23
06/23
NCT04128189: Shingrix in Renal Transplant Recipients

Recruiting
3
132
US
Shingrix
University of Colorado, Denver
Kidney Transplant Recipient Response to Shingrix Vaccine
01/26
09/26
NCT05371080 / 2021-005319-30: A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

Active, not recruiting
3
3038
Europe, Canada, Japan, US, RoW
HZ/su vaccine
GlaxoSmithKline
Herpes Zoster
08/27
08/27
NCT04091451 / 2016-000744-34: Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster

Completed
3
1430
Europe, RoW
Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A), Placebo
GlaxoSmithKline
Herpes Zoster
02/24
02/24
RSV OA=ADJ-020, NCT05966090: A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults

Completed
3
530
Canada, US
RSVPreF3 OA investigational vaccine, Respiratory Syncytial Virus PreFusion protein 3 Older Adults vaccine, HZ/su vaccine, Herpes Zoster recombinant subunit vaccine, Shingrix
GlaxoSmithKline
Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
02/24
07/24
PISSARRO, NCT06890416: A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults

Active, not recruiting
3
526
US
RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, ABRYSVO, RSVpreF, PF-06928316, HZ/su VACCINE, SHINGRIX, RZV, HZ/su
Pfizer
Respiratory Syncytial Virus (RSV)
09/25
09/25
NCT06001606: Immunogenicity, Reactogenicity of Shingrix in SLE

Recruiting
3
63
RoW
Shingrix, Placebo
Seoul National University Hospital
Zoster, Systemic Lupus Erythematosus, Vaccine Reaction
04/25
04/25
NCT03702231: Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Completed
2
116
US
Zoster Vaccine Recombinant, Adjuvanted, SHINGRIX
National Heart, Lung, and Blood Institute (NHLBI)
Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
09/20
07/23
NCT05082688: Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)

Completed
2
148
Europe
Herpes zoster vaccination (Shingrix, GSK), Influenza Vaccine (Fluarix Tetra Northern Hemisphere 2021 or 2022, GSK), Placebo
Radboud University Medical Center, GlaxoSmithKline
Influenza, Herpes Zoster
05/23
05/23
2022-003477-36: Safety and immunologic response of SHIngrix VAccination in patients suffering from Psoriasis or Psoriatic arthritis (SHIVAP) Sicherheit und Immunantwort der Shingrix-Impfung bei Patienten mit Schuppenflechte oder Schuppenflechte mit Gelenkentzündung

Not yet recruiting
2
336
Europe
Powder and suspension for suspension for injection, Shingrix
Justus-Liebig University Giessen - KKS Marburg-Giessen, GSK
Psoriasis vulgaris and/or psoriatric arthritis, Psoriasis and/or psoriatric arthritis Schuppenflechte und/oder Schuppenflechte mit Gelenkentzündung, Body processes [G] - Immune system processes [G12]
 
 
BMS-188667, NCT03604406: The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept

Active, not recruiting
2
154
US
Varicella Zoster Vaccine, Zostavax, Placebo Injection, Shingrix
Kevin Winthrop, University of Alabama at Birmingham, Bristol-Myers Squibb
Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis
06/25
09/26
NCT04047979: Systems Biology of Zoster Vaccine

Completed
2
38
US
Shingrix®
Emory University, National Institute of Allergy and Infectious Diseases (NIAID)
Zoster, Zoster Varicella, Shingles, Chicken Pox
04/23
10/23
NCT05856084: Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above

Active, not recruiting
2
924
RoW
Low dose Recombinant Herpes Zoster Vaccine (CHO cells), High dose Recombinant Herpes Zoster Vaccine (CHO cells), Positive control, Shingrix®, Placebo, Normal Saline for injection
MAXVAX Biotechnology Limited Liability Company, Henan Center for Disease Control and Prevention
Herpes Zoster
02/24
03/26
NCT05304351: Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

Recruiting
2
1516
US
Amezosvatein Antigen High Dose Arm A, Amezosvatein Antigen Low Dose Arm B, Shingrix, Amezosvatein Adjuvant Dose Arm D, Amezosvatein Adjuvant Dose Arm F, Amezosvatein Adjuvant Dose Arm H, Amezosvatein Adjuvant Dose Arm J, Amezosvatein Adjuvant Dose Arm L
Curevo Inc, Mogam Biotechnology Research Institute, Green Cross Corporation
Herpes Zoster, Shingles
06/26
03/32
JCXH-105-021, NCT06581575: A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

Active, not recruiting
2
467
US
JCXH-105, Shingrix
Immorna Biotherapeutics, Inc., Tigermed Consulting Co., Ltd
Herpes Zoster (HZ), Infectious Diseases, Shingles
08/25
08/25
NCT05554068: Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Recruiting
2
100
US
Shingrix
Loyola University
Shingles
03/25
11/26
Allo, NCT05775718: Shingrix In Recipients of geneic Transplants

Recruiting
2
55
US
Zoster Vaccine Recombinant, Shingrix
University of Colorado, Denver, GlaxoSmithKline
Bone Marrow Transplant, Stem Cell Transplant
12/25
12/30
NCT05703607: A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

Active, not recruiting
2
900
US
Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection, Candidate 3: PF-07921186: VZV modRNA Suspension for Injection, Shingrix, Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection
Pfizer, BioNTech SE
Shingles, Herpes Zoster Infection, Human
02/26
08/30
NCT06569823: Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults

Recruiting
1/2
440
RoW
Z-1018, Shingrix
Dynavax Technologies Corporation
Shingles, Herpes Zoster, Vaccine-Preventable Diseases
09/26
09/26
NCT05701800: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

Active, not recruiting
1/2
659
US
mRNA-1468, Placebo, Saline, Shingrix
ModernaTX, Inc.
Herpes Zoster
06/26
06/26
NCT06801509: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine

Not yet recruiting
1/2
540
RoW
Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose, Recombinant Herpes Zoster Vaccine (SCTV04C) High-Dose, Placebo control: Saline, Shingrix®, Ganwei®
Sinocelltech Ltd.
Herpes Zoster
11/25
10/27
NCT06932523: A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals

Not yet recruiting
1/2
645
NA
Recombinant herpes zoster vaccine with low-dose adjuvant, Recombinant herpes zoster vaccine with high-dose adjuvant, Low-dose adjuvant, High-dose adjuvant, Shingrix (GSK), Normal Saline
Shanghai Institute Of Biological Products
Herpes Zoster (HZ)
06/26
12/27
NCT05580458: Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population

Recruiting
1/2
225
US
Shingrix
National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster
02/27
10/27
NH-Shingrix, NCT04523246: Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents

Completed
1
217
US
SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted), Zoster Vaccine Recombinant, Adjuvanted, Normal Saline, saline
University of Oklahoma, Oklahoma Medical Research Foundation
Herpes Zoster, Allergy and Immunology, Corona Virus Infection
12/21
05/23
NCT06137755: Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above

Recruiting
1
32
RoW
CVI-VZV-001, Shingrix
CHA Vaccine Institute Co., Ltd.
Vaccine-Preventable Diseases, Herpes Zoster
03/25
03/25
NCT05769049: The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell)

Completed
1
48
RoW
REC610, Recombinant Zoster Vaccine (CHO cell), Shingrix
Jiangsu Rec-Biotechnology Co., Ltd.
Herpes Zoster
12/23
12/23
NCT05718037: Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine

Not yet recruiting
1
40
NA
Recombinant Zoster Vaccine, BV211, Placebo, Zoster Vaccine Recombinant, Adjuvanted, Shingrix
Wuhan BravoVax Co., Ltd., Shanghai BravoBio Co., Ltd.
Herpes Zoster
01/24
07/24
JCXH-105, NCT05871541: A First-in-Human Study to Evaluate , an SrRNA-based Herpes Zoster Vaccine

Completed
1
75
US
JCXH-105, Active Control (Shingrix)
Immorna Biotherapeutics, Inc., ICON plc
Herpes Zoster (HZ), Shingles, Infectious Disease
03/24
03/24
LYB004-CT-AUS-101, NCT06335849: A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 50 to 70 Years

Active, not recruiting
1
48
RoW
LYB004 25µg, LYB004 50µg, SHINGRIX
Guangzhou Patronus Biotech Co., Ltd., Yantai Patronus Biotech Co., Ltd.
Herpes Zoster
09/25
09/25
NCT06375512: A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

Active, not recruiting
1
150
US, RoW
HZ Vaccine (IN001), Placebo, Shingrix
Shenzhen Shenxin Biotechnology Co., Ltd
Herpes Zoster
12/25
06/26
NCT06409494: Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years

Active, not recruiting
1
72
RoW
EuHZV, Shingrix
EuBiologics Co.,Ltd
Varicella Zoster Virus Infection, Herpes Zoster
07/25
05/26
NCT05991427: A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years

Completed
1
65
Canada
Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV), Zoster Vaccine Recombinant, Adjuvanted (Shingrix), ChAdOx1-VZV, Shingrix, IH ChAdOx1-VZV, IH saline
CanSino Biologics Inc.
Herpes Zoster
11/24
11/24
MKKCT-100-001, NCT05636436: Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above

Active, not recruiting
1
132
RoW
Low Dose Recombinant Herpes Zoster Vaccine (CHO cells), High Dose Recombinant Herpes Zoster Vaccine (CHO cells), Low dose adjuvant, High dose adjuvant, Positive control, Shingrix®, Placebo, Saline for injection
MAXVAX Biotechnology Limited Liability Company, Henan Center for Disease Control and Prevention
Herpes Zoster
12/24
12/24
NCT06874842: Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older

Recruiting
1
92
RoW
Low dose antigen and low dose adjuvant of LYB004, Low dose antigen and high dose adjuvant of LYB004, High dose antigen and low dose adjuvant of LYB004, High dose antigen and high dose adjuvant of LYB004, Placebo, Positive control, Shingrix®
Guangzhou Patronus Biotech Co., Ltd.
Herpes Zoster (HZ)
02/26
10/26
SIR ZOSTER, NCT06262776: Safety and Immunogenicity of Recombinant Zoster Vaccine for Kidney Transplant Recipients

Recruiting
N/A
120
RoW
Recombinant zoster vaccine adjuvanted (SHINGRIX)
Central Adelaide Local Health Network Incorporated, National Health and Medical Research Council, Australia, University of Adelaide, Royal Prince Alfred Hospital, Sydney, Australia
Immunosuppression, Vaccine Response Impaired
12/25
12/26
NCT06238726: Nudging Patients to Increase Shingles Vaccination

Completed
N/A
50786
US
Reminder
Geisinger Clinic, Massachusetts Institute of Technology, National Bureau of Economic Research, Inc.
Shingles, Vaccination Behavior, Behavior, Health
06/25
06/25
CLL2624, NCT06364033: Biological and Clinical Efficacy of Shingrix in Patients With CLL

Not yet recruiting
N/A
312
Europe
serologic response evaluation
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL-like MBL, Varicella-zoster Virus Reactivation
11/25
10/28
NCT06574594: Effect of MTX Discontinuation on Shingrix Response in RA

Recruiting
N/A
110
RoW
Methotrexate
Konkuk University Medical Center
Rheumatoid Arthritis
12/25
12/25
NCT06596148: Improving Shingrix Vaccination Among US Veterans Receiving Immunosuppression

Enrolling by invitation
N/A
130
US
Access to Shingrix dashboard
University of California, San Francisco, San Francisco Veterans Affairs Medical Center
Immunosuppresion
03/26
06/26
NCT05811754: Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions

Not yet recruiting
N/A
2844
NA
Data collection
GlaxoSmithKline, Harvard Pilgrim Health Care Institute
Herpes Zoster
05/28
04/29
Cervarix (recombinant human papillomavirus bivalent vaccine) / GSK, Japan Vaccine
2007-006651-39: A phase IV, randomized, open-label, controlled, post-licensure study to evaluate the safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix®) when administered intramuscularly according to a 0, 1, 6-month schedule in females aged 18-25 years.

Ongoing
4
100000
Europe
Cervarix ™, HPV-16/18 L1 VLP AS04 vaccine, Cervarix ™, Havrix®, Cervarix ™, Havrix®
GlaxoSmithKline Biologicals
No medical condition will be investigated in this study. The study will follow vaccinated females and collect safety data focussing on autoimmune diseases, pregnancy outcomes and SAEs considered to be related to the vaccine.
 
 
2008-006773-32: A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving Cervarix(TM) or Gardasil(TM) Human Papillomavirus vaccines

Ongoing
4
400
Europe
Cervarix, Gardasil, Cervarix, Gardasil, Cervarix, Gardasil
Health Protection Agency
This study will investigate vaccines that prevent premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18. This study will investigate whether immunisation against infection with HPV 16 and 18 may impact on other oncogenic HPV types, through cross-protection.
 
 
NCT03675256: The KEN SHE Study on HPV-vaccine Efficacy

Active, not recruiting
4
2275
RoW
immediate Gardasil 9, delayed MenVeo vaccine, immediate MenVeo vaccine, delayed Gardasil 9, immediate Cervarix, delayed MenVeo vaccine
Massachusetts General Hospital, Bill and Melinda Gates Foundation, Kenya Medical Research Institute
Papillomavirus Infections
02/24
02/24
NCT03180034: Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study

Active, not recruiting
4
28000
RoW
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Adacel, Daptacel, Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine Adsorbed, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine, DTaP, Infanrix, Tripedia, Questionnaire Administration, Recombinant Human Papillomavirus Bivalent Vaccine, Cervarix, GSK-580299, HPV 16/18 L1 VLP/AS04 VAC, HPV-16/18 VLP/AS04 Vaccine, Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine, Human Papillomavirus Bivalent Types 16 and 18 Vaccine, Recombinant, Human Papillomavirus Vaccine L1 16,18, Human Papillomavirus Vaccine, L1 Type 16, 18, Recombinant HPV Bivalent Vaccine, Recombinant Human Papillomavirus Nonavalent Vaccine, Gardasil 9, Nonavalent HPV VLP Vaccine, Recombinant HPV Nonavalent Vaccine, Recombinant Human Papillomavirus 9-valent Vaccine
National Cancer Institute (NCI), Bill and Melinda Gates Foundation
Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma
08/25
08/25
PRISMA, NCT05237947: Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The ESCUDDO Trial

Active, not recruiting
4
5000
RoW
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Adacel, Daptacel, Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine Adsorbed, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine, DTaP, Infanrix, Tripedia, Questionnaire Administration, Recombinant Human Papillomavirus Bivalent Vaccine, Cervarix, GSK-580299, HPV 16/18 L1 VLP/AS04 VAC, HPV-16/18 VLP/AS04 Vaccine, Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine, Human Papillomavirus Bivalent Types 16 and 18 Vaccine, Recombinant, Human Papillomavirus Vaccine L1 16,18, Human Papillomavirus Vaccine, L1 Type 16, 18, Recombinant HPV Bivalent Vaccine, Recombinant Human Papillomavirus Nonavalent Vaccine, Gardasil 9, Nonavalent HPV VLP Vaccine, Recombinant HPV Nonavalent Vaccine, Recombinant Human Papillomavirus 9-valent Vaccine
National Cancer Institute (NCI)
Human Papillomavirus-Related Cervical Carcinoma
05/26
05/26
NCT02834637: A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls

Active, not recruiting
3
930
RoW
bivalent HPV vaccine, Cervarix, nonavalent HPV vaccine, Gardasil9
London School of Hygiene and Tropical Medicine, University of York, Institut Català d'Oncologia, National Cancer Institute (NCI), Karolinska Institutet, Technische Universität Berlin, Tanzanian National Institute for Medical Research, University of Glasgow
Human Papilloma Virus
01/20
03/27
PRIMAVERA-ESCUDDO, NCT03728881: Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the Trial

Completed
3
1240
RoW
Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine, Gardasil, Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle vaccine, quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine, Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine, V501, Recombinant Human Papillomavirus Bivalent Vaccine, Cervarix, GSK-580299, HPV 16/18 L1 VLP/AS04 VAC, HPV-16/18 VLP/AS04 Vaccine, Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine, Human Papillomavirus Bivalent Types 16 and 18 Vaccine, Recombinant, Human Papillomavirus Vaccine L1 16,18, Human Papillomavirus Vaccine, L1 Type 16, 18, Recombinant HPV Bivalent Vaccine
National Cancer Institute (NCI)
Human Papillomavirus-Related Cervical Carcinoma
09/22
04/24
2007-000164-24: Safety and immunogenicity study of GlaxoSmithKline Biologicals’ HPV-16/18/33/58 L1 VLP vaccine in healthy female subjects aged 18–25 years

Not yet recruiting
1/2
540
Europe
HPV-16/18/33/58 L1 VLP AS04 vaccine, HPV-16/18/33/58 L1 VLP AS01E vaccine, HPV-16/18/33/58 L1 VLP AS02W vaccine, HPV-16/18/33/58 L1 VLP AS04 vaccine, HPV-16/18/33/58 L1 VLP AS01E vaccine, HPV-16/18/33/58 L1 VLP AS02W vaccine, Suspension for injection, Cervarix
GlaxoSmithKline Biologicals, GlaxoSmithKline Biologicals
Healthy volunteers, Cervical cancer, Diseases [C] - Cancer [C04]
 
 
HVRRICANE, NCT04301154: Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth

Active, not recruiting
1
25
RoW
HIVIS DNA/MVA-CMDR, HIVIS DNA + Cervarix and MVA-CMDR, Cervarix
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bambino Gesù Hospital and Research Institute, PENTA Foundation, Johns Hopkins University, University of Miami, Leidos Biomedical Research, Inc., Case Western Reserve University, Karolinska Institutet, Walter Reed Army Institute of Research (WRAIR), Armed Forces Research Institute of Medical Sciences, Thailand, University of Padova, Chulalongkorn University
HIV Infections
10/23
02/25
IVIHPV1, NCT03747770: Effectiveness of Single Dose or Two Doses of Bivalent HPV Vaccine in Thailand

Enrolling by invitation
N/A
18000
RoW
Bivalent HPV vaccine CERVARIX®
International Vaccine Institute, Ministry of Health, Thailand
Healthy
12/22
06/23

Download Options